News

Us2.ai Receives CE Mark for Latest AI Echocardiography Capabilities, Unlocking Fully Automated Analysis and Single-View Cardiac Amyloid Detection Across Europe

Us2.ai is powering AI-driven echocardiography at Erasmus MC and Wilhelmina Hospital Assen (WZA), two leading hospitals in the Netherlands.

Presented as a Late-Breaking Science at Heart Failure 2025 in Belgrade, Serbia, Heart2Miss showcased a groundbreaking model for early heart failure detection in Malaysia. The programme trained bioscience graduates through a focused four-week course in handheld ultrasound and AI-assisted analysis (Us2.ai). Beyond diagnostics, Heart2Miss also demonstrated a reduction of burden on tertiary care, streamlined referrals, and created new healthcare career pathways through innovative workforce development.

In this interview at ACC.25, The Cardiac Wire Show spotlighted how Us2.ai is transforming echocardiography and showcased the various integration pathways now available. With FDA-cleared technology, Us2.ai fully automates expert-level echo analysis—producing results in under two minutes with no manual input and 100% reproducibility. What once took 45–60 minutes for a full echo workflow can now be completed in just 20–30 minutes. This innovation is especially impactful in the face of a global sonographer shortage and growing clinical demands.

Presented at ACC.25, this study highlights an AI-powered workflow for assessing tricuspid regurgitation severity. Developed in collaboration with The Chinese University of Hong Kong, the tool offers fast, consistent, and expert-level analysis—advancing precision in echocardiographic diagnosis.

In this interview, Dr. Wojciech Mazur, MD, Director of Advanced Cardiac Imaging at The Christ Hospital Health Network, and Dave Ladd, Business Development at Us2.ai, discuss the integration of AI-driven echocardiography into clinical practice.

Us2.ai and FUJIFILM Healthcare Americas Corporation, have partnered to equip Fujifilm’s LISENDO 800 cardiovascular ultrasound system with Us2.ai’s artificial intelligence (AI)-driven, automated clinical workflow solution.

2024 for Us2.ai was a year of remarkable milestones, impactful partnerships, and significant progress in our mission to improve patient outcomes and expand healthcare access. From securing FDA clearance for Us2.v2 to being featured in over 35 research publications and abstracts, we’ve also expanded partnerships and advanced clinical adoption, driving real-world impact in cardiac care.

Take a look at some of our biggest highlights from the year!

Us2.ai has been successfully deployed at The University of Medicine and Pharmacy, Ho Chi Minh City, making it the first hospital in Vietnam to implement AI for echocardiography.

Presented at the Late Breaking Science session at EuroEcho–Imaging 2024, the results from this multi-centre international study provides strong scientific evidence for Us2.ai’s unique approach, combining black-box pattern recognition with measurement-based methods, to improve CA detection and diagnosis with greater precision and automation.